Platelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome

Efe E., Kocayigit I., Turker P. M., Murat K., Erkan A., Sedat T., ...Daha Fazla

INDIAN JOURNAL OF PHARMACOLOGY, cilt.48, sa.4, ss.355-359, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 48 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.4103/0253-7613.186205
  • Dergi Adı: INDIAN JOURNAL OF PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.355-359
  • Anahtar Kelimeler: Acute coronary syndrome, clopidogrel, drug resistance, lymphocyte, neutrophil, platelet, MYOCARDIAL-INFARCTION, PROGNOSTIC MARKER, ASPIRIN, ASSOCIATION, RESISTANCE, COUNT, INTERVENTION, AGGREGATION, SEVERITY, DEATH
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives: Dual antiplatelet therapy (DAPT), consisting of clopidogrel and aspirin, is the main-stay treatment of acute coronary syndromes (ACS). However, major adverse cardiovascular events may occur even in patients undergoing DAPT, and this has been related to the variable pharmacodynamic efficacy of these drugs, especially clopidogrel. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) are novel inflammatory markers for cardiovascular risk stratification, which may reflect an inflammatory state and thus high on-treatment platelet reactivity (HPR).